- Home
- GALT vs FHTX Comparison
GALT vs FHTX Comparison
Compare GALT & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- FHTX
- Stock Information
- Founded
- GALT 2000
- FHTX 2015
- Country
- GALT United States
- FHTX United States
- Employees
- GALT N/A
- FHTX N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- GALT Health Care
- FHTX Health Care
- Exchange
- GALT Nasdaq
- FHTX Nasdaq
- Market Cap
- GALT 232.3M
- FHTX 278.1M
- IPO Year
- GALT N/A
- FHTX 2020
- Fundamental
- Price
- GALT $3.57
- FHTX $4.98
- Analyst Decision
- GALT Strong Buy
- FHTX Strong Buy
- Analyst Count
- GALT 3
- FHTX 8
- Target Price
- GALT $6.00
- FHTX $12.63
- AVG Volume (30 Days)
- GALT 299.1K
- FHTX 106.1K
- Earning Date
- GALT 08-14-2025
- FHTX 08-05-2025
- Dividend Yield
- GALT N/A
- FHTX N/A
- EPS Growth
- GALT N/A
- FHTX N/A
- EPS
- GALT N/A
- FHTX N/A
- Revenue
- GALT N/A
- FHTX $24,173,000.00
- Revenue This Year
- GALT N/A
- FHTX $33.60
- Revenue Next Year
- GALT N/A
- FHTX $5.87
- P/E Ratio
- GALT N/A
- FHTX N/A
- Revenue Growth
- GALT N/A
- FHTX N/A
- 52 Week Low
- GALT $0.73
- FHTX $2.95
- 52 Week High
- GALT $4.41
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- GALT 58.06
- FHTX 44.97
- Support Level
- GALT $3.55
- FHTX $4.48
- Resistance Level
- GALT $3.90
- FHTX $5.23
- Average True Range (ATR)
- GALT 0.32
- FHTX 0.39
- MACD
- GALT -0.04
- FHTX -0.07
- Stochastic Oscillator
- GALT 41.67
- FHTX 23.65
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.